Everyman - Funding research to cross out male cancer
Everyman is the UK's leading male cancer campaign
Virgin Money and Everyman Partner to Fight Male Cancer
11 January 2006
Virgin Money, the financial services arm of the Virgin brand, has teamed up with The Everyman Campaign with the aim of raising over £250,000 to help fund vital research into testicular and prostate cancer, through a series of fundraising events taking place in 2006.
The ongoing partnership will see Virgin Money and Everyman working together to stage a variety of events and activities designed to raise money and to educate men and women about the signs and symptoms of male cancer. The events will be announced later in the spring when the first is due to take place.
With the recent launch of its new cancer insurance product, 'The Big V', Virgin Money wanted to join the fight against cancer, choosing to support Everyman.Sir Richard Branson, Chairman of Virgin Money commented "We are delighted to be working in partnership with Everyman to raise funds for research and to increase awareness. We wanted to support Everyman because male cancer doesn't just affect men, but their families and partners also and because research into these cancers has traditionally been under-funded. Our partnership with Everyman gives us the opportunity to help address this."
Philip Black, Director of Fundraising at Everyman said, "We are very excited about the partnership with Virgin Money. Through our joint fundraising events we will be able to raise a substantial amount of money to help fund research at The Everyman Centre - Europe's first and only centre dedicated to male cancer research."The Everyman Campaign is run by The Institute of Cancer Research to raise awareness of, and fund research into, testicular and prostate cancer at The Everyman Centre.
For further information or to request an interview with an Everyman or Virgin Money spokesperson, please contact:
The Everyman Campaign
Tel: 0207 153 5312
Notes to editors:
About Virgin Money:
Unfortunately the press office are unable to answer queries from the general public. For general cancer information please refer to The Institute's cancer information page.